Roth/MKM Starts CG Oncology (CGON) at Buy

Roth/MKM analyst Ben Paluch initiates coverage on CG Oncology (NASDAQ: CGON) with a Buy rating and a price target of $65.00.

The analyst comments "We initiate coverage of CG Oncology with a Buy rating and $65 price target. We anticipate share momentum as cretostimogene approaches a 2H25 BLA submission in BCG-unresponsive, high-risk non-muscle invasive bladder cancer (HR-NMIBC). We view cretostimogene's tolerability as a major differentiator, which could help gain market share from competitors that have tolerability issues in this setting. We believe promising cretostimogene efficacy bodes well for intermediate-risk NMIBC (IR-NMIBC). We see potential for $2B + in 2033 worldwide sales of creostimogene in BCG-unresponsive, HR- and IR-NMIBC."

For an analyst ratings summary and ratings history on CG Oncology click here. For more ratings news on CG Oncology click here.

Shares of CG Oncology closed at $37.74 yesterday.

You May Also Be Interested In

• Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
• Macquarie Starts VNET Group Inc (VNET) at Outperform
• Hilton (HLT) call put ratio 1.1 calls to 1 put into quarter results